William Bush, MD
Internal Medicine · Harrisburg, PANPI 1982636841
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 424 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 10.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,456 and has fallen 76.3% since, to $345 in 2025. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 424 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$652
- GSK$623
- AbbVie$607
- Lilly USA, LLC$602
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$570
- AstraZeneca$496
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,494100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 39 | $652 |
| GSK | 44 | $623 |
| AbbVie(2 entities) | 43 | $607 |
| Lilly USA, LLC | 35 | $602 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $570 |
| AstraZeneca | 28 | $496 |
| E.r. Squibb & Sons, L.L.C. | 16 | $351 |
| Kowa Pharmaceuticals America, Inc. | 22 | $296 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $294 |
| Exact Sciences | 10 | $229 |
| Sanofi-aventis U.S. LLC | 12 | $200 |
| Novo Nordisk | 9 | $164 |
| Boehringer Ingelheim | 9 | $152 |
| Mylan Specialty L.p. | 8 | $119 |
| Novartis | 7 | $115 |
| IBSA Pharma Inc. | 6 | $109 |
| Merck | 6 | $103 |
| Genentech USA, Inc. | 5 | $94 |
| Johnson & Johnson | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 5 | $83 |
| Almatica Pharma LLC | 4 | $78 |
| Idorsia Pharmaceuticals US Inc | 4 | $74 |
| Jazz Pharmaceuticals Inc. | 3 | $62 |
| Paratek Pharmaceuticals, Inc. | 3 | $58 |
| Astellas Pharma US Inc | 3 | $54 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Amgen | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
How this compares
$6,517 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $109,109 |
| OzempicSemaglutide | 61 | $69,621 |
| OxycontinOxycodone Hcl | 26 | $58,427 |
| JanuviaSitagliptin Phosphate | 43 | $48,000 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $42,692 |
| FarxigaDapagliflozin Propanediol | 53 | $38,949 |
| TrulicityDulaglutide | 25 | $36,067 |
| XareltoRivaroxaban | 45 | $33,789 |
| Humulin R U-500Insulin Regular, Human | 12 | $33,746 |
| MounjaroTirzepatide | 30 | $29,835 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $20,519 |
| EntrestoSacubitril/Valsartan | 13 | $14,259 |
| RybelsusSemaglutide | 14 | $12,647 |
| TrintellixVortioxetine Hydrobromide | 25 | $11,361 |
| MyrbetriqMirabegron | 12 | $11,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $652 | $109,109113 claims |
| Novo NordiskOzempic, Rybelsus | $164 | $82,26875 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $602 | $65,90255 claims |
| MerckJanuvia | $103 | $48,00043 claims |
| AstraZenecaFarxiga | $496 | $38,94953 claims |
| Johnson & JohnsonXarelto | $92 | $33,78945 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $623 | $31,40543 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $294 | $15,93637 claims |
| NovartisEntresto | $115 | $14,25913 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $11,30812 claims |
| Boehringer IngelheimCombivent Respimat | $152 | $10,74016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Harrisburg
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.